Core Insights - LifeMD (NASDAQ: LFMD) has seen a price increase of approximately 46% since the last article published nearly a year ago, indicating positive market performance and investor interest in the company's Weight Management Program [1]. Company Overview - LifeMD is focused on innovative healthcare solutions, particularly in the realm of weight management, which is expected to influence its profitability timeline [1]. Investment Opportunities - The article highlights the potential for LifeMD's Weight Management Program to serve as a catalyst for future growth and profitability, suggesting that investors may find opportunities in this area [1].

Core Insights - LifeMD, Inc. has launched a limited-time introductory bundle for new self-pay patients, offering Wegovy at a discounted price of $199 along with access to its virtual weight management program for a total first-month cost of $299 [1][2] - The collaboration with Novo Nordisk enhances LifeMD's ability to provide branded GLP-1 medications through a fully integrated care experience, catering to the increasing number of self-pay patients seeking FDA-approved treatments [2][4] - The program will cost $599 per month starting from the second month, with no long-term commitment required [3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory, and pharmacy services across more than 200 conditions, including weight management [6] - The company utilizes a vertically integrated platform, which includes a 50-state medical group and national diagnostic lab partnerships, to ensure a seamless experience from consultation to ongoing support [4][6] Product Offering - Wegovy is the first GLP-1 therapy approved in the U.S. for chronic weight management and cardiovascular risk reduction in adults with obesity, available in an injector pen by prescription for eligible LifeMD patients [5]

Company Overview - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [1] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to enhance access to high-quality and affordable care [1] Investor Engagement - Management will participate in several investor conferences in May, including the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, the B. Riley Securities 25th Annual Institutional Investor Conference on May 21-22, and the Craig-Hallum 22nd Annual Institutional Investor Conference on May 28 [2] - At these conferences, management will hold one-on-one meetings with investors and present a corporate overview [2]

Core Viewpoint - LifeMD, Inc. reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, marking a significant improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 125% [1] Financial Performance - LifeMD posted revenues of $65.7 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.20%, compared to revenues of $44.14 million in the same quarter last year [2] - Over the last four quarters, the company has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - LifeMD shares have increased approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $64.9 million, and for the current fiscal year, it is $0.06 on revenues of $267.95 million [7] Industry Outlook - The Medical Services industry, to which LifeMD belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8]

Financial Data and Key Metrics Changes - LifeMD achieved total revenues of $65.7 million, a 49% increase year over year [12] - Core telehealth revenue grew by 70% compared to the prior year, with adjusted EBITDA of $5.3 million, a significant improvement from a loss of $1.3 million in the same period last year [12][15] - GAAP net income attributable to common stockholders was $608,000, compared to a net loss of $7.5 million in the first quarter of 2024 [14] - Adjusted EBITDA totaled $8.7 million for the first quarter, compared to $100,000 in the year-ago period [15] - Gross margin for the first quarter was 86.8%, a decline of 270 basis points year over year but an increase of 150 basis points sequentially [12][13] Business Line Data and Key Metrics Changes - The telehealth business saw a 22% increase in active subscribers, reaching over 290,000 [12] - WorkSimply active subscribers declined by 5% to 158,000, but the business continued to perform well financially with quarterly adjusted EBITDA exceeding $3 million [12] - The RExMD brand showed consistent growth in revenue and active patient count, reinforcing its position in men's health [5] Market Data and Key Metrics Changes - LifeMD expanded coverage to over 21 million Medicare Part B beneficiaries across 26 states, with plans to reach 49 states and over 60 million beneficiaries by the end of Q2 [9] - The company is entering high-growth verticals such as women's health and behavioral health, with new offerings expected to launch soon [10][11] Company Strategy and Development Direction - LifeMD aims to build a trusted vertically integrated marketplace for healthcare services, prescription medications, and over-the-counter health products [17] - The company is expanding its offerings beyond sexual health into weight management, behavioral health, insomnia, and hormone replacement therapy [6][10] - Strategic collaborations with Lilly Direct and NovoCare are intended to improve access to GLP-1 medications for weight management patients [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the remainder of the year, citing strong early traction across key initiatives [17] - The company is focused on delivering high-quality virtual care and enhancing patient experience through technology and a mission-driven team [18] - Management highlighted the importance of insurance in their offerings, believing it will drive retention and expand the total addressable market [28] Other Important Information - LifeMD's cash position at the end of the first quarter was $34.4 million [16] - The company raised its financial guidance for 2025 due to the outperformance of its telehealth business [16] Q&A Session Summary Question: Can you talk about your relationships with Lilly and Novo? - Management clarified that the pricing for medications is the same for patients regardless of the source, and there are no discounts or rebates from drug manufacturers [23][24] Question: Can you discuss the role of insurance in your offerings? - Management emphasized the importance of insurance in making care more accessible and driving retention, while also acknowledging the complexity of integrating cash pay and insurance offerings [28] Question: What were the main drivers of earnings upside compared to expectations? - The main driver was higher-than-expected retention revenue, with a small contribution from increased acquisitions in the weight management space [31][32] Question: Can you provide an update on your compounding pharmacy? - The compounding pharmacy is on track for licensing, with expectations to scale the mail order pharmacy significantly [33] Question: Does your 2025 guidance include contributions from mental health and women's health? - Yes, but the contributions are expected to be minimal initially, with growth anticipated as the offerings are fully integrated [38] Question: How much of the positive guidance revision is related to the recent pharmacy announcement? - The guidance revision is primarily based on Q1 performance, with potential long-term benefits from the partnerships not yet incorporated into guidance [44][45] Question: How will patients choose between Wegovy and Zepbound? - Patient choice will not affect LifeMD's revenue, as both therapies are offered based on clinical recommendations [50] Question: Will LifeMD continue to offer compounded GLP-1 in the coming years? - LifeMD does not compound GLP-1 medications but will assist patients in accessing branded therapies [56]

Telehealth Performance - Telehealth revenue increased by 70% for the three months ended March 31, 2025, compared to the same period in 2024, with approximately 86% of total revenue coming from recurring subscriptions[133]. - Telehealth revenue accounted for 79.85% of total revenue, increasing to approximately $52.5 million, while WorkSimpli revenue remained consistent at approximately $13.2 million, representing 20.15% of total revenue[144]. - LifeMD's telehealth platform integrates a 50-state medical group and a nationwide pharmacy network, enhancing patient care delivery[130]. Patient Engagement - LifeMD currently serves approximately 291,000 active patient subscribers and has helped over 1,191,000 customers since inception[130]. - The GLP-1 Weight Management Program has grown to approximately 85,000 patient subscribers as of March 31, 2025, following its launch in April 2023[137]. - Rex MD has served more than 638,000 customers and patients to date, focusing on men's health needs[142]. Financial Performance - Total revenue for the three months ended March 31, 2025, was approximately $65.7 million, an increase of 49% compared to $44.1 million for the same period in 2024, driven by a 70% increase in telehealth revenue[144]. - Gross profit increased by approximately 44% to $57.1 million, with gross profit as a percentage of revenues decreasing to approximately 86.84% from 89.58% year-over-year[146]. - Operating income for the three months ended March 31, 2025, was approximately $2.5 million, a significant improvement from a loss of $6.2 million in the same period in 2024[144]. - Net income for the three months ended March 31, 2025, was approximately $1.9 million, compared to a net loss of $6.6 million for the same period in 2024[144]. Expenses and Cash Flow - Total expenses for the three months ended March 31, 2025, were approximately $54.5 million, an increase of 19% compared to $45.7 million for the same period in 2024[147]. - Net cash provided by operating activities was approximately $3.1 million for the three months ended March 31, 2025, down from $5.2 million in the same period in 2024[151]. - The Company has the ability to curtail expenses if necessary, contributing to its positive cash flow outlook[158]. Capital and Investments - The Company utilized approximately $2.9 million in investing activities, primarily for capitalized software costs of approximately $2.7 million[152]. - As of March 31, 2025, there was $19.0 million outstanding under the Avenue Facility, which provides a total credit facility of up to $40 million[156]. - The Company has $53.3 million available under the At Market Issuance Sales Agreement, part of the $150.0 million available under the 2024 Shelf[158]. - The Company received $10 million from Medifast to support collaboration, with $5 million paid at closing on December 12, 2023, and the remaining $5 million paid in installments[158]. - The Company issued 1,224,425 shares in a private placement to Medifast's subsidiary at a price of $8.1671 per share, raising approximately $10 million[159]. Future Outlook - The Company expects to have sufficient cash over the next 12 months due to continued revenue strengthening, reduced losses, and improved operational efficiencies[158]. - The Company anticipates an improvement in its cash burn rate and positive operating cash flows during the three months ended March 31, 2025[158]. - The overall market value of the telehealth industry is expected to drive interest in the Company, evidenced by the collaboration with Medifast[158]. Strategic Initiatives - The company plans to expand insurance acceptance to over 60 million Medicare beneficiaries nationwide by the end of Q2 2025[132]. - The company executed integration with LillyDirect's pharmacy provider to streamline access to obesity treatment for eligible patients[141]. - LifeMD's mission is to empower healthier lives by increasing access to high-quality virtual and in-home healthcare[131]. Accounting and Compliance - The Company is evaluating the impact of recent accounting standards updates on its consolidated financial statements[163][164].

Financial Data and Key Metrics Changes - LifeMD achieved total revenues of $65.7 million, a 49% increase year over year [12] - Core telehealth revenue grew by 70% compared to the prior year, with adjusted EBITDA of $5.3 million, a significant improvement from a loss of $1.3 million in the same period last year [12][14] - GAAP net income attributable to common stockholders was $608,000, or $0.01 per diluted share, compared to a net loss of $7.5 million, or a loss of $0.19 per share, in Q1 2024 [13][14] - Adjusted EBITDA totaled $8.7 million for the first quarter, compared to $100,000 in the year-ago period [14] Business Line Data and Key Metrics Changes - The telehealth business saw a 70% revenue growth, driven by the weight management program and new initiatives like men's hormone therapy [5][12] - Active telehealth subscribers increased by 22% year over year to over 290,000 [12] - WorkSimply active subscribers declined by 5% to 158,000, but the business continued to perform well financially with quarterly adjusted EBITDA exceeding $3 million [12] Market Data and Key Metrics Changes - LifeMD expanded its fee-for-service Medicare coverage to over 21 million beneficiaries across 26 states, with plans to reach 49 states and over 60 million beneficiaries by the end of Q2 [9] - The company is entering high-growth verticals such as women's health and behavioral health, with new offerings expected to launch soon [10][11] Company Strategy and Development Direction - LifeMD aims to build a trusted vertically integrated marketplace for healthcare services, prescription medications, and over-the-counter products [16] - The company is expanding its RExMD brand beyond sexual health into areas like weight management, behavioral health, insomnia, and hormone replacement therapy [6][10] - Strategic collaborations with Lilly Direct and NovoCare are designed to improve access to GLP-1 medications for weight management patients [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the remainder of the year, citing strong early traction across key initiatives [16] - The company is focused on delivering a comprehensive, convenient, and outcomes-driven care experience [11][17] - Management highlighted the importance of insurance in their offerings, believing it enhances accessibility and retention [26] Other Important Information - LifeMD's gross margin for Q1 was 86.8%, a decline of 270 basis points year over year but an increase of 150 basis points sequentially [12][13] - The company raised its financial guidance for 2025, expecting total revenues in the range of $268 million to $275 million [15] Q&A Session Summary Question: Can you talk about your relationships with Lilly and Novo? - Management clarified that the pricing for medications is the same for all patients, regardless of whether they come through LifeMD, and that they do not receive compensation from drug manufacturers [21][22] Question: What is the role of insurance in your offerings? - Management emphasized the importance of insurance in making care more accessible and driving retention, while also acknowledging the complexity it adds to their programs [26] Question: What were the main drivers of earnings upside compared to expectations? - The main driver was stronger-than-expected retention revenue, with a small contribution from higher acquisitions in the weight management space [28][29] Question: Can you provide an update on your compounding pharmacy? - The compounding pharmacy is on track to be licensed by summer, with expectations to scale the mail order pharmacy significantly [30] Question: Does your 2025 guidance include contributions from mental health and women's health? - Yes, but the contributions are expected to be minimal initially, with growth anticipated as the offerings are fully integrated [34] Question: How much of the positive guidance revision is related to the recent pharmacy announcement? - None of the guidance revision is related to the pharmacy announcement; it is based on Q1 performance [40][41]

[First Quarter 2025 Results](index=1&type=section&id=First%20Quarter%202025%20Results) LifeMD achieved its first-ever GAAP profitability in Q1 2025, driven by strong telehealth revenue growth and strategic initiatives, leading to raised full-year guidance [Management Commentary](index=1&type=section&id=Management%20Commentary) Management reported first-ever GAAP profitability in Q1 2025, driven by strong weight management performance and strategic initiatives, leading to raised full-year guidance - Achieved its first-ever quarter of **GAAP profitability**, driven by strong performance in its weight management program and expansion across all service areas[3](index=3&type=chunk) - Strategic collaborations with LillyDirect and NovoCare make LifeMD the only U.S. telehealth provider offering synchronous care and cash-pay access to both Wegovy and Zepbound[4](index=4&type=chunk) - Telehealth revenue grew **70% year-over-year**, and telehealth adjusted EBITDA increased to **$5.3 million** from a loss of $1.3 million in the prior-year period[5](index=5&type=chunk) - Announced key hires in mental and hormonal health and acquired assets in behavioral and women's health to address significant unmet clinical needs[4](index=4&type=chunk) [First Quarter Financial & Operational Highlights](index=1&type=section&id=First%20Quarter%20Financial%20%26%20Operational%20Highlights) Q1 2025 saw total revenues grow 49% to $65.7 million, driven by a 70% telehealth revenue surge, achieving the company's first GAAP net income of $0.6 million Q1 2025 Key Financial Metrics (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $65.7 million | $44.1 million | +49% | | Telehealth Revenue | $52.5 million | $30.8 million | +70% | | GAAP Net Income | $0.6 million | ($7.5 million) | N/A | | Diluted EPS | $0.01 | ($0.19) | N/A | | Adjusted EBITDA | $8.7 million | $0.1 million | +$8.6M | | Telehealth Adjusted EBITDA | $5.3 million | ($1.3 million) | +$6.6M | Q1 2025 Key Performance Metrics (Subscribers) | Subscriber Metric | Q1 2025 | Q1 2024 | Y-o-Y Growth | | :--- | :--- | :--- | :--- | | Telehealth Active Subscribers | 290,660 | 237,790 | 22% | | WorkSimpli Active Subscribers | 158,265 | 166,351 | -5% | | **Total Active Subscribers** | **448,925** | **404,141** | **11%** | - Cash on hand was **$34.4 million** as of March 31, 2025[10](index=10&type=chunk) [Financial Guidance](index=2&type=section&id=Financial%20Guidance) LifeMD raised its full-year 2025 revenue and adjusted EBITDA guidance, reflecting confidence in continued strong performance for Q2 2025 [Q2 2025 Guidance](index=2&type=section&id=Q2%202025%20Guidance) For the second quarter of 2025, the company projects total revenues between $65 million and $67 million and adjusted EBITDA in the range of $7 million to $9 million Q2 2025 Guidance | Metric | Guidance Range | | :--- | :--- | | Total Revenues | $65M - $67M | | Telehealth Revenue | $52M - $53M | | Adjusted EBITDA | $7M - $9M | | Telehealth Adjusted EBITDA | $4M - $6M | [Full-Year 2025 Guidance](index=2&type=section&id=Full-Year%202025%20Guidance) The company has raised its full-year 2025 guidance, with total revenues now expected between $268 million and $275 million, and adjusted EBITDA projected in the range of $31 million to $33 million Updated Full-Year 2025 Guidance | Metric | New Guidance Range | Previous Guidance Range | | :--- | :--- | :--- | | Total Revenues | $268M - $275M | $265M - $275M | | Telehealth Revenue | $208M - $213M | $205M - $213M | | Adjusted EBITDA | $31M - $33M | $30M - $32M | | Telehealth Adjusted EBITDA | Forecast to exceed $21M | Approx. $20M | [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) The consolidated financial statements detail LifeMD's balance sheet, income statement, and cash flow performance, reflecting improved profitability and financial position in Q1 2025 [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, LifeMD reported total assets of $73.6 million, decreased total liabilities to $74.0 million, and improved its stockholders' deficit to $0.4 million Balance Sheet Summary (in millions) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $34.4 | $35.0 | | Total Current Assets | $50.0 | $48.7 | | **Total Assets** | **$73.6** | **$72.5** | | **Liabilities & Equity** | | | | Total Current Liabilities | $60.9 | $60.3 | | Total Liabilities | $74.0 | $76.5 | | Total Stockholders' Equity (Deficit) | ($0.4) | ($4.0) | | **Total Liabilities & Equity** | **$73.6** | **$72.5** | [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 saw a significant turnaround with $0.6 million net income attributable to common stockholders, driven by a 49% revenue increase to $65.7 million and a shift to operating income Statement of Operations Summary (Q1 2025 vs Q1 2024, in millions) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Total Revenues, Net | $65.7 | $44.1 | | Gross Profit | $57.1 | $39.5 | | Operating Income (Loss) | $2.5 | ($6.2) | | Net Income (Loss) Attributable to Common Stockholders | $0.6 | ($7.5) | | Diluted EPS | $0.01 | ($0.19) | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, the company generated $3.1 million in cash from operating activities, used $2.9 million in investing, and ended the quarter with $34.4 million in cash Cash Flow Summary (Q1 2025 vs Q1 2024, in millions) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $3.1 | $5.2 | | Net cash used in investing activities | ($2.9) | ($2.2) | | Net cash used in financing activities | ($0.8) | ($1.0) | | **Net (decrease) increase in cash** | **($0.6)** | **$2.0** | | **Cash at end of period** | **$34.4** | **$35.1** | [Non-GAAP Financial Measures](index=8&type=section&id=Non-GAAP%20Financial%20Measures) LifeMD presents non-GAAP financial measures, including Adjusted EBITDA for consolidated and segment results, to provide a clearer view of core business performance by excluding specific non-recurring or non-cash items [Reconciliation of GAAP Net Income to Consolidated Adjusted EBITDA](index=9&type=section&id=Reconciliation%20of%20GAAP%20Net%20Income%20to%20Consolidated%20Adjusted%20EBITDA) Consolidated Adjusted EBITDA significantly improved to $8.7 million in Q1 2025 from $0.1 million in Q1 2024, reconciled from GAAP net income with adjustments for non-cash items Consolidated Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024, in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net income (loss) attributable to common shareholders | $608 | ($7,545) | | Adjustments (Depreciation, Stock Comp, etc.) | $8,051 | $8,653 | | **Consolidated Adjusted EBITDA** | **$8,659** | **$108** | [Reconciliation of Telehealth Operating Income to Telehealth Adjusted EBITDA](index=10&type=section&id=Reconciliation%20of%20Telehealth%20Operating%20Income%20to%20Telehealth%20Adjusted%20EBITDA) Telehealth segment's Adjusted EBITDA swung to a positive $5.3 million in Q1 2025 from a $1.3 million loss in Q1 2024, reconciled from operating income with key adjustments Telehealth Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024, in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Telehealth operating income (loss) | $387 | ($6,620) | | Adjustments (Depreciation, Stock Comp, etc.) | $4,919 | $5,289 | | **Telehealth Adjusted EBITDA** | **$5,306** | **($1,331)** | [Reconciliation of WorkSimpli Operating Income to WorkSimpli Adjusted EBITDA](index=10&type=section&id=Reconciliation%20of%20WorkSimpli%20Operating%20Income%20to%20WorkSimpli%20Adjusted%20EBITDA) WorkSimpli segment's Adjusted EBITDA more than doubled to $3.4 million in Q1 2025 from $1.4 million in Q1 2024, reconciled from operating income with adjustments WorkSimpli Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024, in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | WorkSimpli operating income | $2,156 | $449 | | Adjustments | $1,197 | $990 | | **WorkSimpli Adjusted EBITDA** | **$3,353** | **$1,439** |

Core Insights - LifeMD, Inc. reported strong financial results for Q1 2025, achieving its first-ever quarter of GAAP profitability ahead of expectations [3][5] - The company experienced significant growth in telehealth services, with a 70% year-over-year increase in telehealth revenue [5][8] - LifeMD raised its full-year 2025 guidance for total revenues and adjusted EBITDA, reflecting robust performance in the telehealth segment [5][14] Financial Performance - Total revenues increased by 49% year-over-year to $65.7 million, with telehealth revenue contributing $52.5 million [8][9] - Adjusted EBITDA rose to $8.7 million from $0.1 million in the same period last year [9][30] - GAAP net income was reported at $0.6 million, or $0.01 per diluted share, compared to a net loss of $7.5 million, or ($0.19) per share, in Q1 2024 [9][21] Subscriber Growth - Telehealth active subscribers increased by 22% to approximately 290,000 [9][10] - Total active subscribers across all services reached 448,925, marking an 11% increase year-over-year [10] Strategic Initiatives - LifeMD expanded its service offerings, including the launch of men's hormone therapy and acceptance of Medicare, which are expected to enhance its telehealth platform [3][4] - The company formed strategic collaborations with LillyDirect and NovoCare to provide access to branded GLP-1 medications, positioning itself as a unique telehealth provider in the U.S. [4] Financial Guidance - For the full year 2025, LifeMD expects total revenues in the range of $268 million to $275 million, up from previous guidance of $265 million to $275 million [5][14] - Adjusted EBITDA guidance was raised to a range of $31 million to $33 million, reflecting strong year-to-date performance [5][14]

Core Viewpoint - Shares of Hims & Hers Health and LifeMD surged significantly after Novo Nordisk announced the distribution of its GLP-1 weight loss drug Wegovy through telehealth platforms, enhancing access for patients [1][2]. Group 1: Company Developments - Hims & Hers Health's stock increased by 24%, while LifeMD's stock rose by 34% as of 3:15 p.m. ET [1]. - Wegovy will be available through Hims & Hers starting at $599 per month, which includes 24/7 care, nutritional guidance, and ongoing clinical support [3]. - LifeMD offers Wegovy at a reduced self-pay cost of $499 per month, including convenient home delivery [3]. Group 2: Market Dynamics - The partnership with Novo Nordisk revives a key revenue driver for Hims & Hers, which previously benefited from a supply shortage of GLP-1 drugs by selling compounded versions [3]. - LifeMD's stock has been less volatile but has declined over the past year [4]. - Hims & Hers is the most recognized telehealth provider and is expected to benefit the most from the partnership due to its brand recognition and existing customer base [5]. Group 3: Financial Metrics - Hims & Hers trades at a high valuation of 53.7 times earnings and 4.6 times sales, which may be considered expensive [5]. - LifeMD trades at a much lower valuation of 1.2 times earnings, despite still operating at a loss, indicating potential for growth [5].